194 related articles for article (PubMed ID: 33790633)
1. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment.
Bai M; Li ZG; Ba Y
Int J Gen Med; 2021; 14():1041-1055. PubMed ID: 33790633
[TBL] [Abstract][Full Text] [Related]
2. Influence of VEGFR2 gene polymorphism on the clinical outcomes of apatinib for patients with chemotherapy-refractory extensive-stage SCLC: a real-world retrospective study.
Geng N; Ding CM; Liu ZK; Song S; Hu WX
Int J Clin Oncol; 2021 Apr; 26(4):670-683. PubMed ID: 33392882
[TBL] [Abstract][Full Text] [Related]
3. The Influence of KDR Genetic Variation on the Efficacy and Safety of Patients With Advanced NSCLC Receiving First-Line Bevacizumab Plus Chemotherapy Regimen.
Geng N; Su J; Liu Z; Ding C; Xie S; Hu W
Technol Cancer Res Treat; 2021; 20():15330338211019433. PubMed ID: 34060368
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
5. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
6. Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the
Song ZZ; Zhao LF; Zuo J; Fan ZS; Wang L; Wang YD
Onco Targets Ther; 2020; 13():603-613. PubMed ID: 32021302
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes and safety of apatinib monotherapy in the treatment of patients with advanced epithelial ovarian carcinoma who progressed after standard regimens and the analysis of the
Yan Z; Gu YY; Hu XD; Zhao Q; Kang HL; Wang M; Duan W; Guan Y
Oncol Lett; 2020 Sep; 20(3):3035-3045. PubMed ID: 32782621
[TBL] [Abstract][Full Text] [Related]
8. [The impact of genetic variation of KDR on clinical outcomes of advanced colorectal cancer patients treated by first line bevacizumab based regimens].
Wang HX; Mei X; Gong TX; Han N; Liu P; Wang J; Zhang ZM
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2737-2742. PubMed ID: 30220171
[No Abstract] [Full Text] [Related]
9. Implication of KDR Polymorphism rs2071559 on Therapeutic Outcomes and Safety of Postoperative Patients with Gastric Cancer Who Received S-1-Based Adjuvant Chemotherapy: A Real-World Exploratory Study.
Meng L; Cao J; Kang L; Xu G; Yuan DW; Li K; Zhu K
Pharmgenomics Pers Med; 2023; 16():1027-1039. PubMed ID: 38046381
[TBL] [Abstract][Full Text] [Related]
10. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study.
Su J; Dai B; Yuan W; Wang G; Zhang Z; Li Z; Liu J; Song J
Cancer Chemother Pharmacol; 2020 May; 85(5):969-978. PubMed ID: 32314029
[TBL] [Abstract][Full Text] [Related]
11. Influence of KDR Genetic Variation on the Effectiveness and Safety of Bevacizumab in the First-Line Treatment for Patients with Advanced Colorectal Cancer.
Wang F; Liu G
Int J Gen Med; 2022; 15():5651-5659. PubMed ID: 35734201
[TBL] [Abstract][Full Text] [Related]
12. Association Between
Hu W; Li B; Geng N; He X; Ge H; Wang P; Ding C
Int J Gen Med; 2021; 14():2703-2714. PubMed ID: 34188525
[TBL] [Abstract][Full Text] [Related]
13. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
14. [The influence of Thymidine Phosphorylase genetic variation on clinical outcomes and safety of colorectal cancer patients received adjuvant chemotherapy after R0 resection].
Du YB; Zhang TF; Cui K; Jin SL; Xi Y; Ma W
Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2569-2573. PubMed ID: 30220141
[No Abstract] [Full Text] [Related]
15. Effectiveness and Safety of Apatinib Plus Programmed Cell Death Protein 1 Blockades for Patients with Treatment-refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study.
Li S; Zheng H; Ge Q; Xia S; Zhang K; Wang C; Wang F
J Cancer Prev; 2023 Sep; 28(3):106-114. PubMed ID: 37830117
[TBL] [Abstract][Full Text] [Related]
16. Implication of
Li X; Cheng Y; Zhu B; Geng M; Yan P; Hu M
Technol Cancer Res Treat; 2022; 21():15330338221080993. PubMed ID: 35443836
[No Abstract] [Full Text] [Related]
17. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
[No Abstract] [Full Text] [Related]
18. [The influence of XRCC1 gene polymorphism on the prognosis and safety of stage Ⅲ patients with colorectal cancer who received oxaliplatin based adjuvant chemotherapy].
Li RX; Shang JH; Sun JF
Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(11):759-765. PubMed ID: 33765714
[No Abstract] [Full Text] [Related]
19. Rs11479 in
Jia X; Zhang T; Sun J; Lin H; Bai T; Qiao Y; Li Y; Li G; Li G; Peng X; Zhang A
Pharmgenomics Pers Med; 2023; 16():277-289. PubMed ID: 37025557
[TBL] [Abstract][Full Text] [Related]
20. Potentially functional genetic variants in KDR gene as prognostic markers in patients with resected colorectal cancer.
Dong G; Guo X; Fu X; Wan S; Zhou F; Myers RE; Bao G; Burkart A; Yang H; Xing J
Cancer Sci; 2012 Mar; 103(3):561-8. PubMed ID: 22182247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
